Fine-tuning the drug approval process.
|Datum:||07 december 2020|
To decide whether to allow a newly developed drug to the market or not, a lot of factors need to be taken into account. Evaluating effects and side effects requires precise standards, sometimes they are life and death decisions. Dr. Don van Ravenzwaaij researches current practices of drug approval from a statistical standpoint. He contributes an inspiring perspective to look at numbers. Since AI research is constantly looking for new ways to evaluate and organize data, looking at common practices of other disciplines can be of great value.